^
Association details:
| Biomarker: | ASXL1 mutation |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug Class: | CDK4 inhibitor + CDK6 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer
Published date:
10/09/2021
Excerpt:
CDK4/6 inhibitors (CDK4/6i) in combination with antiestrogens have prolonged survival of patients with ER+ metastatic breast cancer. However, this combination is not curative mainly due to acquired drug resistance....WES of 76 CDK4/6i resistant tumor biopsies (DFCI/MBCproject cohort) identified ASXL1 alterations in two and four patients with acquired and primary resistance, respectively (6/76=7.9%)....ASXL1 alterations were found in ~8% of tumors from patients with de novo or acquired resistance to CDK4/6i.
